Additional amplified RTKs in cancer include EGFR (7p11.2), FGFR1 (fibroblast growth factor receptor 1; 8p11.23), PDGFRA (platelet-derived growth factor receptor alpha; 4q12), MET (also known as HGFR, hepatocyte growth factor receptor; 7q31.2), FLT3 (FMS-related tyrosine kinase 3; 13q12.2), and AXL (tyrosine protein kinase receptor UFO; 19q13.2) [28,39]. Here, MET is linked to cancer.